Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. by Riva, Beatrice et al.
Thomas Jefferson University
Jefferson Digital Commons
Kimmel Cancer Center Papers, Presentations, and
Grand Rounds Kimmel Cancer Center
11-7-2016
Celecoxib inhibits proliferation and survival of
chronic myelogeous leukemia (CML) cells via
AMPK-dependent regulation of β-catenin and
mTORC1/2.
Beatrice Riva
Università del Piemonte Orientale 'A. Avogadro'
Marco De Dominici
Thomas Jefferson University, Marco.DeDominici@jefferson.edu
Ilaria Gnemmi




Università del Piemonte Orientale 'A. Avogadro'
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/kimmelgrandrounds
Part of the Oncology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Recommended Citation
Riva, Beatrice; De Dominici, Marco; Gnemmi, Ilaria; Mariani, Samanta A.; Minassi, Alberto;
Minieri, Valentina; Salomoni, Paolo; Canonico, Pier Luigi; Genazzani, Armando A; Calabretta,
Bruno; and Condorelli, Fabrizio, "Celecoxib inhibits proliferation and survival of chronic
myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2."
(2016). Kimmel Cancer Center Papers, Presentations, and Grand Rounds. Paper 41.
https://jdc.jefferson.edu/kimmelgrandrounds/41
Authors
Beatrice Riva, Marco De Dominici, Ilaria Gnemmi, Samanta A. Mariani, Alberto Minassi, Valentina Minieri,
Paolo Salomoni, Pier Luigi Canonico, Armando A Genazzani, Bruno Calabretta, and Fabrizio Condorelli
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/kimmelgrandrounds/41
Oncotarget81555www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/             Oncotarget, 2016, Vol. 7, (No. 49), pp: 81555-81570
Celecoxib inhibits proliferation and survival of chronic 
myelogeous leukemia (CML) cells via AMPK-dependent 
regulation of β-catenin and mTORC1/2
Beatrice Riva1, Marco De Dominici2, Ilaria Gnemmi1, Samanta A. Mariani3, Alberto 
Minassi1, Valentina Minieri2, Paolo Salomoni4, Pier Luigi Canonico1, Armando A. 
Genazzani1, Bruno Calabretta2, and Fabrizio Condorelli1
1From Department of Pharmacological Sciences, Università del Piemonte Orientale “A. Avogadro”, 28100 Novara, Italy
2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia 19107, PA, USA
3MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh EH16 4TJ, UK
4Samantha Dickson Brain Cancer Unit, University College London Cancer Institute, London WC1E 6BT, UK
Correspondence to: Fabrizio Condorelli, email: fabrizio.condorelli@uniupo.it
Keywords: celecoxib, chronic myelogenous leukemia, cyclooxygenase-2, beta-catenin, AMP-activated kinase
Received: May 27, 2016    Accepted: October 19, 2016    Published: November 07, 2016
ABSTRACT
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the 
efficacy of these drugs is confined to the chronic phase of the disease and development 
of resistance to TKIs remains a pressing issue. The anti-inflammatory COX2 inhibitor 
celecoxib has been utilized as anti-tumour drug due to its anti-proliferative activity. 
However, its effects in hematological malignancies, in particular CML, have not been 
investigated yet. Thus, we tested biological effects and mechanisms of action of 
celecoxib in Philadelphia-positive (Ph+) CML and ALL cells.
We show here that celecoxib suppresses the growth of Ph+ cell lines by increasing 
G1-phase and apoptotic cells and reducing S- and G2-phase cells. These effects were 
independent of COX2 inhibition but required the rapid activation of AMP-activated 
protein kinase (AMPK) and the consequent inhibition mTORC1 and 2. Treatment 
with celecoxib also restored GSK3β function and led to down-regulation of β-catenin 
activity through transcriptional and post-translational mechanisms, two effects likely 
to contribute to Ph+ cell growth suppression by celecoxib.
Celecoxib inhibited colony formation of TKI-resistant Ph+ cell lines including 
those with the T315I BCR-ABL mutation and acted synergistically with imatinib in 
suppressing colony formation of TKI-sensitive Ph+ cell lines. Finally, it suppressed 
colony formation of CD34+ cells from CML patients, while sparing most CD34+ 
progenitors from healthy donors, and induced apoptosis of primary Ph+ ALL cells.
Together, these findings indicate that celecoxib may serve as a COX2-independent 
lead compound to simultaneously target the mTOR and β-catenin pathways, key 
players in the resistance of CML stem cells to TKIs.
INTRODUCTION
Celecoxib is a sulfonamide COX2 inhibitor (COXib) 
used in the therapy of osteoarthritis and rheumatoid arthritis. 
In addition to its anti-inflammatory activity, celecoxib exerts 
anti-proliferative effects on transformed cells, as shown in 
some solid tumors. In particular, it is the only COXib used 
for the therapy of Familial Adenomatous Polyposis (FAP) 
patients with the goal to prevent its evolution toward colon 
cancer [1-3] by inhibiting the COX2-dependent secretion of 
prostaglandin E2 by adenomatous cells.
Nevertheless, several reports indicate that celecoxib 
exerts cell-autonomous anti-proliferative and pro-
apoptotic effects also in cancer cell lines that do not 
express COX2 [4,5]. In line with these findings, dimethyl-
celecoxib, a close structural analogue of celecoxib that 
lacks anti-COX2 activity (“non-COXib”), mimics the anti-
tumor effects of celecoxib [6-8].
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Alternative targets of celecoxib are at present 
elusive although recent reports have focused on PDK1, 
SERCA, carbonic anhydrase, NFκB, and survivin [9,10], 
all of which are typically inhibited at concentrations higher 
than those usually required for COX2 inhibition [8,11,12].
Chronic myelogenous leukemia (CML), a 
myeloproliferative disorder caused by the BCR-ABL1 
oncoprotein, is an ideal model to dissect COX2-dependent 
and COX2-independent mechanisms of celecoxib growth 
inhibition because the role of many signal transduction 
pathways in CML cell proliferation and survival is 
well established, allowing the effects of celecoxib to be 
linked to the modulation of specific BCR-ABL-regulated 
pathways. Moreover, drugs not previously known to play 
a role in CML, such as the anti-diabetic drug pioglitazone, 
appear to have important and unexpected effects in CML 
[13], raising the possibility that growth-inhibitory effects 
of celecoxib in Ph+ cells may be therapeutically relevant.
In CML, the BCR-ABL chimeric oncoprotein 
which functions as a constitutively active tyrosine kinase 
is also necessary for disease maintenance; thus, CML 
provides an ideal model for testing the effects of “targeted 
therapies”. Indeed, treatment with imatinib or second-
generation tyrosine-kinase inhibitors (TKIs) has markedly 
improved the survival of CML patients; however, 
individual intolerance to these inhibitors, the emergence 
of clones with TKI-resistant BCR-ABL mutations, 
and the observation that leukemia-initiating/stem cells 
are intrinsically resistant to these drugs, in part due to 
overacting PI3K/AKT/mTOR and β-catenin pathways, 
support the ongoing search for new drugs targeting CML 
stem cells [14,15].
We show here that celecoxib, at concentrations near 
those required for its anti-inflammatory effects, suppresses 
proliferation and colony formation of imatinib-sensitive 
and resistant Ph+ cell lines and primary cells, including 
CD34+ CML cells. Of greater importance, celecoxib had 
only modest effects on colony formation of normal CD34+ 
progenitors. Mechanistically, the effects of celecoxib 
appear to be COX2-independent through AMP-dependent 
kinase regulation of mTOR and β-catenin, two important 
mediators of TKI resistance in CML stem cells.
RESULTS
Celecoxib impairs proliferation and induces cell 
death of CML cell lines in a COX2-independent 
manner
The effect of celecoxib on CML viability was 
assessed in three Ph+ CML-blast crisis cell lines (K562, 
LAMA-84, JURL-MK1) treated for 24 hours (Figure 1A). 
Inhibition of proliferation was especially evident in the 
LAMA-84 cell line (EC50 of approximately 23.8 µM), 
while the JURL-MK1 cell line was the least responsive 
(EC50 of 75.2 µM). Longer exposures to celecoxib led to 
a decrease in EC50s (e.g. for 6 days 8.2 µM for LAMA-84 
and 23.8 µM for JURL-MK1; Supplementary Figure S1). 
Then, we assessed whether the anti-proliferative effect of 
celecoxib was due to COX2 inhibition. Immunoblots of 
cell lysates revealed that the three cell lines express very 
low levels of COX1, which is not targeted by celecoxib, 
whereas expression of COX2 was not detectable 
(Figure 1B). We also assessed the anti-proliferative effects 
of dimethyl-celecoxib, an analogue unable to inhibit 
COX2 [11] and of rofecoxib, a structurally distinct COX2 
inhibitor. Dimethyl-celecoxib exhibited an EC50 of 16.8 
µM in LAMA-84 at 24 hours. By contrast, rofecoxib had 
no effect, even at the highest concentration (25 µM) tested 
for 72 hours (Figure 1C).
The therapeutic potential of putative anti-leukemia 
drugs is best measured by evaluating how efficiently 
they suppress colony formation in a semisolid medium. 
When cells were grown in culture media containing 
80% methylcellulose, celecoxib or dimethyl-celecoxib 
suppressed colony formation in a concentration-dependent 
manner (Figure 1D) and, as expected, their activity was 
not due to inhibition of COX2 since rofecoxib had no 
effect. Again, LAMA-84 cells were the most sensitive to 
treatment with celecoxib or dimethyl-celecoxib; however, 
the EC50 of celecoxib calculated on the basis of the 
methylcellulose assay (0.5 µM; Figure 1D) was markedly 
lower than that based on the MTT assays (8.2 µM, after 6 
days; Supplementary Figure S1).
As shown in Figure 1A, celecoxib, at concentrations 
lower than 25 µM, has a cytostatic rather than a cytotoxic 
effect, as MTT absorbance at 24 hours is not inferior to 
that at the zero time-point. This was confirmed when cell 
counts were used as a direct measure (data not shown).
Single cell DNA content analysis of propidium 
iodide-stained nuclei showed that celecoxib (25 µM) 
caused a marked increase in the G1 fraction (78.5 % 
vs. 51.2 % of controls) of LAMA-84 cells (Figure 2A) 
paralleled by a marked decrease of S (15.4 % vs 26.0 % 
of controls) and G2 phase cells (6.1 % vs 22.8 %). Yet, 
trypan blue exclusion data (Figure 2B) and microscopic 
counting of fragmented nuclei stained with Hoechst-33258 
(Figure 2C) revealed that treatment with 25 µM celecoxib 
caused also the death of about 15-20 % of the cells.
Celecoxib impairs the activity of the β-catenin/
Tcf/Lef axis
A great deal of attention has recently been paid 
to the role of signal transduction pathways involved in 
maintaining the self-renewal of leukemic cells. CML 
stem cells appear to rely, among others, on the β-catenin/
Tcf-Lef-dependent transcription program [16]. This 
pathway is aberrantly activated in CML mononuclear 
cells both in the chronic phase and the blast crisis stage 
[17]. In particular, BCR-ABL can inhibit glycogen 
synthase kinase 3-Beta (GSK3β) that regulates 
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ubiquitination and proteasome-dependent degradation 
of β-catenin; in addition, BCR-ABL may directly 
activate the transcriptional function of β-catenin by 
phosphorylating it on tyrosine residues [18,19]. Thus, we 
tested the hypothesis that celecoxib may exert its effect 
on CML cells through negative modulation of β-catenin. 
Indeed, celecoxib (25 µM) caused a marked decrease 
of β-catenin protein expression in LAMA-84 cells 
treated for 2-24 hours. This effect was already visible 
after 2 hours and peaked after a 16-hours treatment 
Figure 1: Effects of celecoxib on CML cell proliferation. A. Cell viability of CML cell lines treated for 24 hours with increasing 
concentrations of celecoxib. According to NCI screening methodology (https://dtp.cancer.gov/discovery_development/nci-60/methodology.
htm), the discrimination between cytostatic and cytotoxic effects in the upper diagram is evidenced by expressing the percentage of growth 
inhibition as [(Ti-Tz)/(C-Tz)] x 100, for concentrations for which Ti>/=Tz, or [(Ti-Tz)/Tz] x 100, for concentrations for which Ti<Tz 
(Tz: time zero; Ti: test growth after 24 hours in presence of the drug; C: control growth after 24 hours in presence of 0.1% DMSO). 
Values are means from three independent experiments ± S.E.M. B. Immunoblots of cyclooxygenase-1 (COX1) and -2 (COX2) in CML 
cell lines. β-actin levels were used to assess equivalence of protein loading. NIH-3T3 and MSTO-211H protein lysates were used as 
positive controls respectively for COX1 and COX2 expression. C. Time-course of LAMA-84 cells viability after treatments with 25 µM 
rofecoxib or dimethyl-celecoxib. Values are means from three independent experiments ± S.E.M. D. Dose-response curves of celecoxib 
(top) and dimethyl-celecoxib (bottom) in colony formation assays of CML cells lines. Cells (1,250/well) were grown for 6 days on 80% 
methylcellulose culture media after treatment with drugs. Open labels indicate treatment with rofecoxib. Ctrl cells were treated with equal 
amounts of DMSO (0.1%). Values represent the mean of three independent experiments in duplicate ±S.E.M.
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Figure 2: Effect of celecoxib on Ph+ cell viability by DNA content analysis. A. LAMA-84 cell-cycle distribution assessed by 
flow cytometry after propidium iodide staining. Results (means ± S.E.M of n=3 samples; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001) depict a 
representative experiment of three experiments that yielded overlapping results. B. Trypan-blue exclusion test on LAMA-84 cells treated 
with celecoxib (25 µM) for 24 hours.A minimum of 100 cells was scored for each condition. Data on table represent the means of three 
independent experiments ± S.E.M. ***P ≤ 0.001 C. UV-fluorescence(60 x magnification) of Hoechst33258-stained LAMA-84 cell nuclei 
after 24-hours treatment. Arrows indicate the fragmented nuclei of apoptotic cells. Data represent mean percentages of apoptotic cells from 
three independent experiments ± S.E.M.
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(Figure 3A). We next assessed whether the effect was 
due to transcriptional regulation of β-catenin expression. 
Indeed, treatment with celecoxib for 2 hours led to a 
marked decrease (almost by 75%) of β-catenin mRNA 
levels as measured by RT-PCR, an effect that lasted for 
24 hours after a single drug treatment (Figure 3B).
We also assessed whether inhibition of proteasome 
activity by treatment with MG132 could restore the 
effect of celecoxib on β-catenin expression. Cells were 
exposed to celecoxib only for 2 hours in order to limit 
its transcriptional effects, although still ensuring a 20% 
reduction of β-catenin levels. As shown in Figure 3C, 
Figure 3: Celecoxib causes β-catenin down-regulation in a GSK3β- and proteasome-dependent manner. A) β-catenin 
protein expression in LAMA-84 cells exposed to celecoxib (25 µM) at different time-points. Numbers underneath lanes represent the 
treated/control ratio of the optical densities of β-catenin immuno-reactive bands. To exclude the influence of spontaneous fluctuations in 
β-catenin expression, at each time-point, protein extracts of drug-treated cells were compared with the respective controls. Levels of β-actin 
were also calculated and used to normalize protein loadings. B. Expression of β-catenin gene (CTNNB1) transcripts in LAMA-84 cells 
treated with celecoxib (25 µM). The levels of CTNNB1 mRNAs were normalized using the expression of GAPDH transcripts as reference. 
Ratios represent means of three independent experiments ± S.E.M. *P ≤ 0.05, **P ≤ 0.01 C. Immunoblots showing that pharmacological 
inhibition of the proteasome reverts the effects of celecoxib on β-catenin protein degradation. LAMA-84 cells were treated for 2 hours (2h) 
with celecoxib (25 µM), MG132 (20 µM), or in combination (Comb). Values displayed underneath lanes represent ratios of the optical 
densities of β-catenin (β-cat) immuno-reactive bands over those of β-actin (β-act). D. Immunoblots showing that celecoxib causes a time-
dependent decrease of GSK3β phosphorylation in LAMA-84 cells. Levels of total GSK3β protein are displayed to account for protein 
loading variations. E. Immunoblot showing that GSK3β inhibition with BIO antagonizes celecoxib-induced down-regulation of β-catenin. 
LAMA-84 cells were treated for 4 hours with 25 µM celecoxib, 10 µM BIO, or a combination of both (Comb). As for Figure 4A, values 
underneath lanes represent ratios between the optical densities of β-catenin and β-actin immuno-reactive bands (β-cat/β-act).
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MG132 treatment alone caused a seven-fold increase of 
β-catenin protein levels in comparison to control treatment 
(0.1% DMSO) but, more importantly, this effect was also 
detected in cells treated with celecoxib.
A pre-condition for the proteasome-dependent 
degradation of β-catenin is its N-terminal phosphorylation 
by GSK3β. To monitor the activity of GSK3β in 
celecoxib-treated cells, we measured the levels of ser-9 
phosphorylation, which denotes the inactive form of the 
kinase [20]. As shown in Figure 3D, celecoxib inhibited 
the phosphorylation of this kinase, already after a 4-h 
treatment. Further proof that GSK3β reactivation played 
a role in the celecoxib-induced proteasomal degradation 
of β-catenin was obtained upon treatment with the GSK3β 
inhibitor BIO (10 µM); exposure to this inhibitor caused, 
on its own, a fourteen-fold increase of β-catenin levels 
Figure 4: Negative modulation of the Tcf/Lef/β-catenin pathway by celecoxib is essential for its biological effects. A, 
B. Celecoxib reduces the levels of the transcriptional-active form of β-catenin in a time- (A) and concentration-dependent manner (B) 
in LAMA-84 cells. In A, optical densities of act-β-cat immuno-reactive bands were normalised by the intensity of β-actin in order to 
calculate treatment-to-control (celecoxib/CTRL) ratios displayed underneath lanes. In B, optical densities of act-β-cat, total β-cat, and 
β-actin immuno-reactive bands (β-act, used to to normalize protein loadings between lanes) were assessed to calculate the act-β-cat/β-cat 
and β-cat/β-act ratios displayed underneath lanes. C. Celecoxib affects the transcription of β-catenin-target genes, c-myc and p16INK4a in 
LAMA-84 cells as measured by RT-PCR. Data were normalized using GAPDH transcripts as reference. The dotted line intercepting the 
vertical axis at the unit indicates mRNA expression in 0.1 % DMSO-treated cells (CTRL). Values represent means of three independent 
experiments ± S.E.M. **P ≤ 0.01. D. Effect of celecoxib in LAMA-84 cells expressing wild-type β-catenin (WT) or its serine-to-tyrosine 
33 mutant (beta-catenin S33Y) assessed via the MTT assay (viability; top) or the colony assay (clonogenicity; bottom). Data represent 
averages of three independent experiments made in duplicate ± S.E.M. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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as compared to mock treatment (0.1% DMSO), an effect 
which was not blocked by simultaneous administration of 
celecoxib (Figure 3E).
Previous studies have shown that cytosolic 
stabilization of unphosphorylated β-catenin allows its 
translocation to the nucleus [21,22]. Thus, immunoblotting 
of lysates of LAMA-84 cells with an antibody recognizing 
only the unphosphorylated form of β-catenin (actβ-
cat), revealed that celecoxib reduced the levels of 
this transcription-competent isoform in a time- and 
concentration-dependent manner (Figure 4A and 4B, 
respectively).
The β-catenin/Tcf/Lef complex trans-activates 
genes with growth-promoting or anti-apoptotic activity. 
One of such target genes is the c-myc oncogene; thus, 
quantitative RT-PCR analysis of c-myc mRNA levels in 
LAMA-84 cells treated with 25 µM celecoxib (for 2, 8 or 
24 hours) revealed a marked decrease (more evident after 
8 hours) in the levels of c-myc transcripts (Figure 4C) and 
protein levels (Supplementary Figure S2), consistent with 
inhibition of active β-catenin.
Nuclear accumulation of β-catenin impairs the 
transcription of the CDKN2A gene, which encodes the 
p16INK4a tumour suppressor protein, with an inhibitory 
effect on cell cycle progression [23,24]. RT-PCR of 
p16INK4a mRNA levels assessed after treatment with 
25 µM celecoxib revealed a significant increase of 
these transcripts, although only after a 24-h treatment 
(Figure 4C).
To establish a correlation between the effect 
of celecoxib on β-catenin protein stability and on 
proliferation/colony formation of Ph+ CML cells, we 
generated a LAMA-84 parental cell line expressing a 
constitutively active mutant form of β-catenin (β-catenin 
S33Y) that cannot be targeted to the proteasome because 
it is not phosphorylated by GSK3β [25,26]. As expected, 
cells expressing the degradation-resistant form of 
β-catenin were significantly more resistant than parental 
cells to either acute (Figure 4D, upper panel) or chronic 
(Figure 4D, lower panel) exposure to celecoxib.
Celecoxib inhibits the activity of mammalian 
target of rapamycin complex 1 (mTORC1) and 2 
(mTORC2)
Since GSK3β causes the disassembly of mTORC1 
[27], we next investigated the effect of celecoxib on 
mTOR and its downstream targets.
Figure 5A shows that celecoxib induced a time-
dependent decrease of ser-2448 phosphorylation, an 
effect that was maximal within 4 hours of treatment. 
Surprisingly, phosphorylation of mTOR on ser-2481 was 
also diminished, although transiently, suggesting that, in 
contrast to rapamycin and its congeners, celecoxib exerts 
its inhibitory activity on both mTORC1 and mTORC2 
complexes [28,29].
In agreement with these findings, treatment with 
celecoxib reduced the phosphorylation of S6 Kinase (p70-
S6K) and eIF4E binding protein (4E-BP1), the two most 
important mTORC1 targets, as demonstrated by use of 
phospho-specific antibodies directed against thr-389 of 
p70S6K and the N-terminal domain of 4E-BP1 (Figure 
5B). Similarly, celecoxib caused also a decrease in the 
phosphorylation of ser-473 Akt, which is the immediate 
target of mTORC2 (Figure 5B).
Since p70-S6K can negatively modulate GSK3β via 
phosphorylation of ser-9, it is possible that celecoxib-induced 
re-activation of GSK3β might be either the reason and/or 
the consequence of an impairment of mTORC1 function. 
Therefore, we used rapamycin (50 nM) to block mTORC1 
activity and assessed whether this treatment recapitulates 
the effects induced by celecoxib. Surprisingly, although 
treatment with 50 nM rapamycin was as effective as 25 µM 
celecoxib in causing a time-dependent reduction of GSK3β 
phosphorylation on ser-9 (with a peak after 4 hours of 
treatment), it did not modify the levels of β-catenin (Figure 
5C). On the other hand, colony formation assays of LAMA-
84 cells treated with rapamycin (50 nM) and/or celecoxib (10 
µM) yielded similar inhibition of GSK3β phosphorylation 
while the combination was much more potent (86.04±3.45% 
reduction vs control) than either drug used alone (celecoxib: 
59.98±3.61%; rapamycin: 67.74±2.04%) (Figure 5D).
The AMP-activated protein kinase (AMPK) 
contributes to the effects of celecoxib through a 
Ca2+-dependent mechanism
The re-activation of GSK3β induced in CML cells 
by both celecoxib and rapamycin suggested that it might 
be the consequence of mTORC1 inhibition rather than its 
cause. Moreover, the inability of rapamycin to entirely 
recapitulate the effects of celecoxib suggested that the 
molecular mechanisms linking treatment with celecoxib 
to impaired mTORC1 activity remain unclear.
It is known that AMPK activity precedes that 
of GSK3β in the inhibition of mTORC1 complex, thus 
placing this complex under the control of both metabolic 
stress and growth factors [30-32]. With this in mind, we 
tested whether celecoxib inhibited mTORC1, primarily 
through the activation of AMPK, an event that may be 
reinforced by re-activation of GSK3β.
As shown in Figure 6A, celecoxib treatment 
increased AMPKα thr-172 phosphorylation, the active 
form of the catalytic subunit, in a concentration-
dependent manner (upper panel) as early as 15 min after 
treatment.
AMPK is switched-on not only in response to a 
metabolic demand, represented by a relative increase of 
AMP over ATP concentration, but also after an increase 
of intracellular calcium, through the Ca2+/calmodulin-
dependent kinase kinase (CaMKK) [29,32]. Thus, we 
investigated which of the two pathways mediates the 
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effect of celecoxib on AMPK using the HeLa human 
cell line that lacks expression of LKB1, the kinase 
responsible of AMP-dependent activation of AMPKα 
[31]. As shown in Figure 6B, phosphorylation of AMPKα 
on thr-172 was induced after treatment with celecoxib, 
suggesting that LKB1 is dispensable for this effect of 
the drug. Conversely, co-administration of the CaMKK 
specific inhibitor, STO-609 (2.5 µg/mL), completely 
abolished the phosphorylation of AMPKα (Figure 6B). 
These effects were also observed in LAMA-84 cells 
(Figure 6B).
The involvement of CAMKK-induced activation of 
AMPK in mediating the effect of celecoxib was further 
supported by MTT assays, where STO609, albeit having 
some intrinsic activity, partially reversed the effect of 
celecoxib (Figure 6C).
To provide conclusive proof for the role played 
by AMPK in the anti-leukemic effect of celecoxib, we 
reduced the expression of its α- catalytic subunit generating 
LAMA-84 cells with low (highGFP; approximately 63% 
reduction; Supplementary Figure S3) or normal (lowGFP) 
levels of AMPKα using RNAi (see methods). Colony 
assays showed that decreased expression of this kinase 
was associated with decreased sensitivity to celecoxib 
treatment (Figure 6D). Moreover, in highGFP cells 
(with low levels of AMPKα), celecoxib failed to down-
regulate both GSK3β and β-catenin expression (Figure 
6E), indicating that activation of AMPK is essential for 
Figure 5: Celecoxib modulates the activity of mTOR kinase. A. Immunoblots of LAMA-84 lysates treated with celecoxib 
(25 µM) to explore mTOR phosphorylation. Values underneath lanes represent the optical densities of p-mTOR immuno-reactive bands 
corrected by the total levels of mTOR. B. Immunoblots of LAMA-84 lysates treated with celecoxib (25 µM) to explore phosphorylation/
activation of mTORC1 and mTORC2 down-stream targets (p-p70S6K thr-389, p-4E-BP1 thr-37/46, pAkt ser-473). Levels of total p70S6K, 
4E-BP1 and Akt are displayed to compare protein loadings between lanes. C. Time-course of GSK3β phosphorylation (p-GSK3β-ser9) and 
β-catenin (β-cat) protein expression following to inhibition of mTORC1 complex in LAMA-84 cells treated with 50 nM rapamycin. Levels 
of β-actin (β-act) are displayed as proof of equal loading between lanes. D. mTORC1 inhibition and CML cell clonogenicity. LAMA-84 
cells were exposed to 50 nM of rapamycin, alone or in combination (Comb) with 10 µM celecoxib. Results are expressed as percentages 
of colonies counted, after 6 days, in drug-treated groups as compared to controls. Data represent averages of three independent experiments 
made in duplicate. *P ≤ 0.05, **P ≤ 0.01.
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the effects of celecoxib. Surprisingly, OSU-03012, a non-
COXib structural analogue of celecoxib that is in clinical 
development for the treatment of lymphoma patients and 
has been described as PDK1 inhibitor [33,34], reproduced 
the effects of celecoxib (Supplementary Figure S4), 
suggesting that activation of AMPK might be also relevant 
for the effects of this compound.
In support of the central role of AMPK activation for 
the effects of celecoxib, metformin, a first-line medication 
in the treatment of type II diabetes known to activate 
Figure 6: AMP-dependent kinase (AMPK) is activated by celecoxib in a Ca2+-dependent, AMP-independent, manner. 
A. Concentration-response curve of celecoxib (top) and time-course using 25 µM celecoxib (bottom) of activation/phosphorylation of 
AMPK in LAMA-84 cells. Protein lysates were probed with antibodies that recognize the α-subunit of AMPK (AMPK) or its active 
form phosphorylated on thr-172 (p-AMPKα). Values underneath lanes express the ratio of the optical densities of p-AMPKα over total 
AMPK immuno-reactive bands. B. Celecoxib-induced activation of AMPK relies on Ca2+/calmodulin kinase kinase (CaMKK) function. 
The LKB1-deficient human cell line HeLa (upper panel) or LAMA-84 (bottom) were treated with 25 µM celecoxib (for 30 minutes), the 
CaMKK inhibitor STO609 (2.5 µg/mL, 4 hours), or a combination of both (Comb). Protein lysates were probed with AMPK or p-AMPKα 
specific antibodies. C. Inhibition of CaMKK limits the effect of celecoxib on CML blasts viability. LAMA-84 cells were treated for 24 
hours with 25 µM celecoxib, 2.5 µg/ml STO609, or both, as described in Figure 6B. Histograms describe percent reductions of MTT values. 
Values are mean of three independent experiments ± S.E.M. **P ≤ 0.01. D. Dose-response curves of the colony assay of lowGFP (basal 
expression of AMPKα) and highGFP (low expression of AMPKα) LAMA-84 cells exposed to celecoxib. Cell colonies were scored 6 days 
after treatment and seeding. Values represent the average of three independent experiments in duplicate, ± S.E.M. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001 E. GSK3β phosphorylation (p-GSK3β; top) and β-catenin (bottom) protein levels in lowGFP (basal expression of AMPKα) 
and highGFP (low expression of AMPKα) LAMA-84 cells. Ratios between the optical densities of p-GSK3β and GSK3β immuno-reactive 
bands are displayed underneath lanes of the top panel. Values displayed underneath lanes of the bottom panel are the ratio of the optical 
densities of the β-catenin immuno-reactive band over that of β-actin.
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AMPK [35], acted similarly to celecoxib in suppressing 
CML cells growth (MTT, colony assays and cell cycle 
profiles are displayed in Supplementary Figure S5).
Effects of celecoxib, alone or with imatinib, on 
colony formation of Ph+ cell lines (TKI-sensitive 
or resistant) and primary CD34+ CML and acute 
lymphoblastic leukemia (ALL) cells
TKIs are the cornerstones of current CML therapy, 
although resistance to these drugs is frequently observed. 
Thus, we tested the effect of celecoxib in imatinib-resistant 
CML-blast crisis cells. As shown in Figure 7A, 25 µM 
celecoxib or dimethyl-celecoxib, but not indomethacin 
(a COX1 and COX2 inhibitor), completely eradicated 
colony formation of three Ph+ TKI-resistant cell lines 
(BV173R, K562R, KCL22R; for details see the paragraph 
dedicated to in vitro cell lines in “materials and methods”).
We also tested whether imatinib and celecoxib 
have additive effects on the clonogenicity of TKI-
sensitive LAMA-84 CML-blast crisis cells. As shown 
in Figure 7B, celecoxib, although used at a sub-optimal 
concentration (10 µM), potentiated the inhibitory effect 
of a therapeutic dose of imatinib (1 µM). Importantly, 
the Combination Index (CI) of the celecoxib/imatinib co-
treatment, calculated on the inhibition of colony formation 
obtained by crossing four different concentrations of the 
two drugs (corresponding, respectively, to their EC20, 40, 
60, 80), was less than one, indicating that this drug-drug 
interaction is synergistic according to Loewe’s rule [36].
To determine whether celecoxib affects also the 
proliferation and survival of primary CML blasts, we 
performed colony assays of CD34+ cells from four chronic-
phase CML patients. Strikingly, treatment with 25 µM 
of either celecoxib or dimethyl-celecoxib suppressed 
almost entirely CML cell colony formation (Figure 7C, 
white columns). By contrast, these treatments spared a 
sizable number of colonies derived from normal CD34+ 
progenitors (Figure 7C, black columns), demonstrating a 
relative selectivity of celecoxib and dimethyl-celecoxib 
toward BCR-ABL-expressing cells.
Finally, treatment with celecoxib or its dimethyl 
derivative suppressed the proliferation of Ph+ blasts 
isolated from ALL patients, including one resistant to 
imatinib and ponatinib, as assessed by means of cell 
counting (Supplementary Figure S6). Of note, this 
effect was associated with a significant increase of 
apoptosis, as indicated by detection of caspase 3 activity 
(Supplementary Figure S6).
DISCUSSION
The evidence that TKI-based therapies are unable 
to eradicate CML stem cells supports the ongoing search 
for novel treatments that, by targeting these cells, may 
prevent disease relapse or transition to blast crisis [37]. A 
recent work focusing on the use of the anti-diabetic drug 
pioglitazone [13] has demonstrated that such treatments 
may be identified among those originally validated 
for diverse applications. A drug that may have similar 
behaviour is celecoxib since, in addition to its COX2-
dependent anti-inflammatory activity, it is the only COXib 
that suppresses proliferation of cancer cells through 
unclear mechanisms. Indeed, celecoxib induces similar 
growth-inhibitory effects in COX2(+/+), COX2(+/-) and 
COX2(-/-) mouse embryo fibroblasts, as well as in COX2-
negative hematopoietic cell lines, including the K562 line 
[38-40], raising the question of which ones are the relevant 
targets of celecoxib in cancer cells.
We show here that the growth suppression of 
Ph+ CML and ALL cells by celecoxib treatment is due 
primarily to a COX2-independent mechanism based on the 
rapid activation (within minutes) of AMPK, most likely 
through Ca2+-dependent induction of the upstream kinase, 
CaMKK. The involvement of the latter kinase would be 
in partial agreement with Pyrko and colleagues [10], who 
demonstrated that celecoxib is able to induce Ca2+ release 
from endoplasmic reticulum (ER) stores. However, in 
contrast to Pyrko and colleagues, we were unable to detect 
activation of ER stress response following celecoxib 
treatment in LAMA-84 cells (data not shown).
Activation of AMPK seems to precede mTORC1 
and mTORC2 inhibition, restoration of GSK3β activity, 
β-catenin down-regulation and the impairment of CML 
cell proliferation. Accordingly, partial knock-down of 
AMPKα expression is sufficient to restrain the molecular 
events described above as well as the anti-leukemic effect 
of celecoxib. In support of the central role of AMPK in the 
molecular and biological events triggered by celecoxib, 
other groups have demonstrated that activation of AMPK, 
in presence of functional p53, may activate the G1/S 
checkpoint, leading to replicative senescence of cancer 
cells [41]. In line with this observation, we demonstrated 
that celecoxib is able to increase the transcription of 
p16INKa, a prototypical marker of senescence [42].
Activation of AMPK would also explain the 
ability of celecoxib to impair at least mTORC1, since 
AMPK restores the inhibitory action of Rheb onto this 
protein complex. Moreover, inhibition of mTORC1, 
on its own, is likely to cause GSK3β re-activation 
due to the suppression of S6K kinase, which normally 
phosphorylates GSK3β [25,43]. Thus, it was not 
surprising that there was a similar decrease in colony 
formation of CML cells after treatment with celecoxib or 
the mTORC1 inhibitor rapamycin. However, co-treatment 
experiments revealed more effective inhibition of CML 
colony formation, suggesting non-redundant mechanisms 
of action of these two drugs. Indeed, celecoxib, but not 
rapamycin, impaired Akt phosphorylation, most likely 
via inhibition of mTORC2. Moreover, only celecoxib 
caused down-regulation of β-catenin, an event that is 
highly relevant for its anti-leukemic activity. In this 
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Figure 7: Effect of celecoxib, dimethyl-celecoxib, or the COX1/COX2 inhibitor indomethacin on colony formation of 
Ph+ CML cells and normal CD34+ progenitors. A. Colony assay of imatinib-resistant (IM-R) CML blasts (cell lines: BV173R, 
K562R, KCL22R) treated with celecoxib (25 µM) or dimethyl-celecoxib (25 µM; DMC). Indomethacin (Indo; 50 µM), a COX1 and 
COX2 inhibitor, was included as a control. Values are the means of three independent experiments made in duplicate ± S.E.M. ***P 
≤ 0.001. B. Colony assay of LAMA-84 cells treated with celecoxib (10 µM) and/or imatinib (1 µM). Values are the means of three 
independent experiments in duplicate ± S.E.M. **P ≤ 0.01. C. Colony assay of celecoxib or dimethyl-celecoxib (DMC) treated CD34+ 
CML cells (mean of 4 different samples) or normal cord blood-derived CD34+ cells from healthy donors (HD; mean of 4 different samples). 
Cells were treated with 25 µM of either drug before seeding (10,000 cells/plate) onto 80% methylcellulose in the presence of a cytokine 
cocktail. Colonies were scored after 9 days; ***P ≤ 0. 001.
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regard, several groups have demonstrated that activation 
of the Wnt/β-catenin/Tcf-Lef pathway is essential for 
maintaining the self-renewal of leukemic stem cell 
(LSC) [22]. Moreover, it is becoming clear that aberrant 
activation of the β-catenin/Tcf-Lef axis promotes the 
transition of CML from chronic phase to blast crisis 
[19,21,22]. Indeed, BCR-ABL enables β-catenin-
driven transcription independently of Wnt stimulation, 
since: i) it inhibits the GSK3β-dependent degradation of 
β-catenin; and ii) facilitates the interaction of β-catenin 
with Tcf/Lef [44]. Based on these observations, Heidel 
and colleagues [19] hypothesized that inhibition of 
canonical Wnt signalling would hamper CML resistance 
to imatinib, thereby maximizing the therapeutic benefit 
of a co-treatment with TKIs. In agreement with this 
concept, celecoxib reduced the clonogenic potential of 
TKI-resistant CML cells (including cell lines carrying the 
T315I BCR-ABL mutation) and synergized with imatinib 
upon co-treatment of TKI-responsive cells. Intriguingly, 
induction of β-catenin degradation by celecoxib has been 
previously reported in human colon carcinoma [45].
In favour of a possible therapeutic use of celecoxib 
in the management of CML patients, we found that, in 
contrast to what described for TKIs [46,47], this drug 
does not activate autophagy despite its ability to impair 
mTORC1 (data not shown); although this may seem 
contradictory, it is known that mTORC1 inhibition does 
not invariably induce the autophagic response, as already 
shown for rapamycin [48].
Even more translationally-relevant, celecoxib also 
suppressed proliferation and colony formation and induced 
apoptosis of CD34+ CML cells and primary Ph+ ALL cells, 
respectively; this effect appears to be relatively selective 
as it was significantly less pronounced in normal CD34+ 
progenitors from healthy donors.
The argument most commonly used against the 
specificity of COX2-independent, anti-proliferative, 
effects of celecoxib is that they were observed at drug 
concentrations higher than 100 µM. In this regard, most 
of our experiments were performed at a concentration 
of 10-25 µM and the colony assays demonstrated that 
celecoxib may be active even at lower concentrations, 
with an EC50 of 0.5 µM in the LAMA-84 cell line. These 
data are important since it was shown that, at least in 
mice, plasmatic concentrations as high as 45 µM are well 
tolerated in vivo [49]. Noteworthy, due to the lipophilic 
nature of celecoxib, this drug is concentrated three to 
four times more in the bone marrow than in plasma [49]; 
therefore, a concentration of 25 µM celecoxib in the 
hematopoietic compartment can be achieved at a dose of 
950 mg, not too far from the daily dose commonly used 
in the treatment of FAP patients (800 mg, divided in two 
administrations).
We have shown that celecoxib is able to inhibit CML 
blast proliferation and survival, in vitro and in patient-
derived cells, at therapeutically-relevant concentrations, 
through AMPK-dependent impairment of mTOR and 
β-catenin activity. This mechanism is COX2-independent 
and is mimicked by dimethyl-celecoxib and OSU03012, 
a drug currently being examined in clinical trials, but 
not by rofecoxib and indomethacin, two COX2-specific 
inhibitors. Given the good tolerability of celecoxib and 
OSU-03012, these findings support further investigations 
of these agents for the treatment of Ph+ hematological 
malignancies.
MATERIALS AND METHODS
In vitro cell cultures
K562, LAMA-84, JURL-MK1, HeLa were 
obtained from the American Type Culture Collection 
(ATCC, Rockville, MD, USA). BV173 CML-lymphoid 
blast crisis cell line and the imatinib-resistant cell lines 
BV173R (carrying the T315I mutation of BCR-ABL 
oncoprotein; [50]), KCL-22R (which gained imatinib 
resistance with a BCR-ABL-independent mechanism 
and through chromosomal aberrations; [51]), and K562R 
(which is imatinib-resistant through upregulation of Lyn 
kinase [52]), were kindly provided by Dr N.J. Donato 
(University of Michigan). Cells were grown according to 
ATCC instructions and kept in culture at 37 °C, under a 
5% CO2 humidified atmosphere
The LAMA-84 cell line expressing the β-catenin 
S33Y mutant was obtained by gene transfection (see 
details in the text) and was maintained in a RPMI-1640-
based medium, as described for the parental cell line.
AMPKα-silenced cells and their scramble-
transduced counterpart, SCR, were obtained by lentiviral 
delivery of microRNAs (see further in the text), and were 
cultured as the parental LAMA-84 cell line.
In vitro culture of Ph+ primary leukemia cells
Primary Ph+ ALL bone marrow cells were kindly 
provided by Dr Michael Caligiuri (Ohio State University, 
Columbus, OH) and Dr Martin Carroll (University of 
Pennsylvania, Philadelphia, PA). Cells were seeded on a 
substrate of adherent, mitomycin C-treated OP9 stromal 
cells and maintained in SFEM (Stem Cell Technology, 
Vancouver, Canada) supplemented with IL-3 (10 ng/ml), 
IL-7 (10 ng/ml), FLT3L (20 ng/ml) and SCF (30 ng/ml) 
(ProSpec, Israel).
CD34+ CML cells were kindly provided by Dr Tessa 
Holyoake (University of Glasgow, United Kingdom) and 
cultured in SFEM supplemented with IL-3 (20 ng/ml), 
IL-6 (20 ng/ml), SCF, and thrombopoietin (10 ng/ml).
Commercially purchased (Stem Cell Technologies) 
cord blood CD34+ cells were cultured in SFEM (Stem Cell 
Technologies) enriched with the CC100 cytokine cocktail 
(SCF, 100 ng/ml; FLT3L, 100 ng/ml; IL-3, 20 ng/ml; IL-6, 
20 ng/ml).
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Ph+ and normal CD34+ primary cells were kept in 
culture at 37 °C, under a 5% CO2 humidified atmosphere. 
Cell counts were performed using 0.4% Trypan Blue 
Solution and a Neubauer hemocytometer.
Chemicals and antibodies
A list of chemicals used and their suppliers is 
provided in Supplementary Material. 2,5-dimethyl-
celecoxib was synthesized by Prof Minassi according to 
published methods [53].
3-(4,5-Dimethylthiazol-2-Yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assay
MTT assays were performed according to standard 
procedures.
Analysis of cell cycle distribution by flow 
cytometry
Propidium iodide staining of DNA content was 
performed as described [54] and cell cycle analysis was 
performed in an Accuri-C6 flow cytometer and analysed 
using ModFit LT software.
Staining of apoptotic nuclei
Nuclear DNA integrity was assessed through 
microscopy of cells stained with the DNA-binding, 
supravital dye, Hoechst-33342 (Sigma-Aldrich Inc., 
Milan, Italy). Caspase activation assay. Activated Caspase 
3-7 was detected with CellEvent Caspase 3-7 Green 
Detection Reagent (Life Technologies) after washing with 
PBS Ph+ ALL cells seeded on the feeder layer of OP9 
stromal cells.
Colony formation assays
Cells were treated, for 24 hours at a density of 
1x105cells/mL, with the concentrations indicated for 
each drug or with vehicle (0.1% DMSO). Next, 1,250 (or 
10,000 for primary CML) cells/well were seeded into a 
semisolid culture media consisting of 80% methylcellulose 
(MethoCult, STEMCELL Tech., Milan, Italy) and 20% 
RPMI-1640 (fully supplemented) or in methylcellulose 
medium supplemented with a cytokine cocktail (CC100; 
Stem Cell Technologies). After 6-10 days, colonies were 
counted using a phase-contrast microscope.
Immunoblottings
Whole-cell extracts were obtained using the RIPA 
lysis buffer (50 mM Tris-HCl pH 7.4; 150 mM NaCl, 0.5 
mM EDTA pH 8, 1% Igepal, 0.1% SDS), supplemented 
with 1 mM phenylmethylsulphonyl fluoride, 1 mM 
sodium orthovanadate, 50 mM sodium fluoride, 10 mM 
glycerophosphate, 0.5 mM dithiothreitol and standard 
protease inhibitor cocktail (Roche Applied Science, 
Indianapolis, IN, USA). Lysates were clarified by 
centrifugation at 14,000g for 15 min at 4°C and equal 
amount of proteins (30 µg) were loaded on SDS-PAGE 
gels.
Antibodies were all prepared in TRIS-buffered 
saline solution containing with 0.1% Tween-20 (T-TBS), 
and supplemented with 3-5% non-fat dried milk or 3-5% 
bovine serum albumin, depending on the indications of the 
manufacturers.
RNA extraction, reverse transcription and 
quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted from approximately 5 
x106 cells using TRI-Reagent (Sigma Aldrich Inc., Milan, 
Italy) and retrotrascribed using Im-Prom-II Reverse 
Transcriptase (Promega, WI, USA).
After setting gradient PCRs to verify primers 
specificity and melting temperature, standard curves of 
SYBR Green fluorescence were generated for each gene 
tested in order to evaluate primer efficiency.
qRT-PCRs were performed on a 96-well plate, 
in triplicate, and fluorescence intensity assessed using 
the CFX96 Real-Time PCR Detection Systems (Bio-
Rad Inc., Milan, Italy). The following conditions were 
adopted: 12.5 µL Maxima SYBR Green/ROX qPCR 
Master Mix (Thermo Fisher Scientific Inc., Milan, Italy), 
0.1 µM of forward and reverse primers, and 5 µL of 
1:5 diluted cDNA, in a total volume of 25 µL/reaction. 
A list of the primers used (human CTNNB1, human 
c-myc, human p16INK4a, human GAPDH) is presented in 
the Supplementary Section. Transcripts were normalized 
to the expression of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNAs. For each gene, the 
threshold cycle (Ct) was calculated using CFX Manager 
Software (Bio-Rad Inc., Milan, Italy). The Ct of treated 
cells was compared to the Ct generated by the control cells 
and Ct was calculated as the difference between Ct values, 
determined using the equation 2-Ct.
Plasmids, transfection, and lentiviral infections
LAMA-84 β-catenin S33Y cells were obtained by 
stable transfection of a pcDNA3 plasmid carrying the 
cDNA for a FLAG-tagged degradation-resistant mutant 
of β-catenin in which serine 33 has been replaced by a 
tyrosine (Addgene, Cambridge, MA, USA). Cells were 
selected for 10 days with G418 (0.8 mg/mL; Sigma 
Aldrich Inc., Milan, Italy). Expression of the exogenous 
protein (S33Y β-catenin) was verified by immunoblots 
with the anti-FLAG rabbit polyclonal antibody.
Lentiviral bicistronic vectors (pGIPZ) carrying 
the reporter gene turbo-Green Fluorescence Protein 
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(tGFP) and non-targeting (SCR) or -specific miRNAs 
(all obtained through the Open Biosystems library of the 
University College of London Cancer Institute) were used 
to knock-down expression of AMPKα in LAMA-84 cells. 
Viruses were prepared as described in the supplementary 
section. The efficiency of nine different clones of AMPKα-
specific miRNAs was assessed preliminarily through 
western blotting with anti-AMPKα rabbit polyclonal 
antibody (Cell Signaling Technology Inc., Danvers, 
MA, USA). Flow cytometry and cell sorting by means 
of green-fluorescence intensity (the FL1-A parameter, 
BioRad S3) were used to dissect high-expressing (top10% 
of the FL1-A channel, indicated as highGFP) from low 
expressing (bottom 10%, indicated as lowGFP) cells. 
HighGFP cells, having the least AMPKα expression, 
were routinely compared to lowGFP cells, which express 
AMPKα at levels comparable to wild-type LAMA-84 
cells.
Statistical analysis
The results in this study are presented as mean 
S.E.M of the results obtained from independent 
experiments. Statistical analyses were performed using 
Student’s t-test and significance was indicated as follows: 
P<0.05 (*), P<0.01 (**), P<0.001 (***).
ACKNOWLEDGMENTS
The work of Ilaria Gnemmi was supported, in part, 
by a fellowship from the Italian Society of Pharmacology 
(SIF) in collaboration with Merck Sharp&Dome (MSD) 
and by “intramural” funding from Università del Piemonte 
Orientale. Work in Dr Calabretta’s laboratory was 
supported, in part, by NCI grant CA167169.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of 
interest with the contents of this article.
Authors contribution
BR, IG, and MDD equally contributed to most 
of the experiments in the characterization of celecoxib 
mechanism of action in LAMA-84 cells. SAM was 
responsible for the experiments with BV173 cell lines 
and the ex vivo studies with CD34+ cells from CML 
patients and healthy donors. VM was responsible for the 
in vitro studies with Ph+ ALL cells. PS contributed to 
the realization of experiments to knock-down AMPKα 
expression. AAG and PLC contributed to editing of the 
manuscript. BC designed the experiments with primary 
Ph+ cells and edited the manuscript. FC was responsible 
for the overall design of the experiments and for writing 
the manuscript.
REFERENCES
1. Pang, R. P., Zhou, J. G., Zeng, Z. R., Li, X. Y., Chen, W., 
Chen, M. H., and Hu, P. J. Celecoxib induces apoptosis 
in COX2 deficient human gastric cancer cells through 
Akt/GSK3beta/NAG-1 pathway. Cancer Lett. 2007; 251: 
268-277.
2. Phillips, R. K., Wallace, M. H., Lynch, P. M., Hawk, E., 
Gordon, G. B., Saunders, B. P., Wakabayashi, N., Shen, 
Y., Zimmerman, S., Godio, L., Rodrigues-Bigas, M., Su, 
L. K., Sherman, J., Kelloff, G., Levin, B., Steinbach, G., 
and Group, F. A. P. S. A randomised, double blind, placebo 
controlled study of celecoxib, a selective cyclooxygenase 
2 inhibitor, on duodenal polyposis in familial adenomatous 
polyposis. Gut. 2002; 50: 857-860.
3. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. 
H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, 
B., Shen, Y., Fujimura, T., Su, L. K., Levin, B., Godio, L., 
Patterson, S., Rodriguez-Bigas, M. A., Jester, S. L., King, 
K. L., Schumacher, M., Abbruzzese, J., DuBois, R. N., 
Hittelman, W. N., Zimmerman, S., Sherman, J. W., and 
Kelloff, G. The effect of celecoxib, a cyclooxygenase-2 
inhibitor, in familial adenomatous polyposis. N Engl J Med. 
2000; 342: 1946-1952.
4. Goluboff, E. T., Shabsigh, A., Saidi, J. A., Weinstein, I. 
B., Mitra, N., Heitjan, D., Piazza, G. A., Pamukcu, R., 
Buttyan, R., and Olsson, C. A. Exisulind (sulindac sulfone) 
suppresses growth of human prostate cancer in a nude 
mouse xenograft model by increasing apoptosis. Urology. 
1999; 53: 440-445.
5. Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., 
Staiano-Coico, L., Shiff, S. I., and Rigas, B. Effects of 
nonsteroidal anti-inflammatory drugs on proliferation 
and on induction of apoptosis in colon cancer cells by a 
prostaglandin-independent pathway. Biochem Pharmacol. 
1996; 52: 237-245.
6. Kardosh, A., Golden, E. B., Pyrko, P., Uddin, J., Hofman, F. 
M., Chen, T. C., Louie, S. G., Petasis, N. A., and Schonthal, 
A. H. Aggravated endoplasmic reticulum stress as a basis 
for enhanced glioblastoma cell killing by bortezomib in 
combination with celecoxib or its non-coxib analogue, 
2,5-dimethyl-celecoxib. Cancer Res. 2008; 68: 843-851.
7. Kardosh, A., Wang, W., Uddin, J., Petasis, N. A., Hofman, 
F. M., Chen, T. C., and Schonthal, A. H. Dimethyl-
celecoxib (DMC), a derivative of celecoxib that lacks 
cyclooxygenase-2-inhibitory function, potently mimics the 
anti-tumor effects of celecoxib on Burkitt’s lymphoma in 
vitro and in vivo. Cancer Biol Ther. 2005; 4: 571-582.
8. Schonthal, A. H. Direct non-cyclooxygenase-2 targets of 
celecoxib and their potential relevance for cancer therapy. 
Br J Cancer. 2007; 97: 1465-1468.
9. Jendrossek, V. Targeting apoptosis pathways by Celecoxib 
in cancer. Cancer Lett. 2013; 332: 313-324.
10. Pyrko, P., Kardosh, A., Liu, Y. T., Soriano, N., Xiong, W., 
Chow, R. H., Uddin, J., Petasis, N. A., Mircheff, A. K., 
Oncotarget81569www.impactjournals.com/oncotarget
Farley, R. A., Louie, S. G., Chen, T. C., and Schonthal, A. H. 
Calcium-activated endoplasmic reticulum stress as a major 
component of tumor cell death induced by 2,5-dimethyl-
celecoxib, a non-coxib analogue of celecoxib. Mol Cancer 
Ther. 2007; 6: 1262-1275.
11. Schonthal, A. H. Antitumor properties of dimethyl-
celecoxib, a derivative of celecoxib that does not inhibit 
cyclooxygenase-2: implications for glioma therapy. 
Neurosurg Focus. 2006; 20: E21.
12. Song, X., Lin, H. P., Johnson, A. J., Tseng, P. H., Yang, Y. T., 
Kulp, S. K., and Chen, C. S. Cyclooxygenase-2, player or 
spectator in cyclooxygenase-2 inhibitor-induced apoptosis in 
prostate cancer cells. J Natl Cancer Inst. 2002; 94: 585-591.
13. Prost, S., Relouzat, F., Spentchian, M., Ouzegdouh, Y., 
Saliba, J., Massonnet, G., Beressi, J.P., Verhoeyen, E., 
Raggueneau, V., Maneglier, B., Castaigne, S., Chomienne, 
C., Chrétien, S., Rousselot, P., Leboulch, P. Erosion of 
the chronic myeloid leukaemia stem cell pool by PPARγ 
agonists. Nature. 2015; 525: 380-383.
14. Crews, L. A., and Jamieson, C. H. Selective elimination of 
leukemia stem cells: hitting a moving target. Cancer Lett. 
2013; 338: 15-22.
15. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., 
Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical 
resistance to STI-571 cancer therapy caused by BCR-
ABL gene mutation or amplification. Science. 2001; 293: 
876-880.
16. Chen, R., Hu, T., Mahon, G. M., Tala, I., Pannucci, N. 
L., Ozer, H. L., and Whitehead, I. P. Ubiquitin-mediated 
interaction of p210 BCR-ABL with beta-catenin supports 
disease progression in a murine model for chronic 
myelogenous leukemia. Blood. 2013; 122: 2114-2124.
17. Fu, Y., Zheng, S., An, N., Athanasopoulos, T., Popplewell, 
L., Liang, A., Li, K., Hu, C., and Zhu, Y. beta-catenin as a 
potential key target for tumor suppression. Int J Cancer. 
2011; 129: 1541-1551.
18. Coluccia, A. M., Vacca, A., Dunach, M., Mologni, L., 
Redaelli, S., Bustos, V. H., Benati, D., Pinna, L. A., 
and Gambacorti-Passerini, C. Bcr-Abl stabilizes beta-
catenin in chronic myeloid leukemia through its tyrosine 
phosphorylation. EMBO J. 2007; 26: 1456-1466.
19. Heidel, F. H., Bullinger, L., Feng, Z., Wang, Z., Neff, T. 
A., Stein, L., Kalaitzidis, D., Lane, S. W., and Armstrong, 
S. A. Genetic and pharmacologic inhibition of beta-catenin 
targets imatinib-resistant leukemia stem cells in CML. Cell 
Stem Cell. 2012; 10: 412-424.
20. Doble, B. W., Patel, S., Wood, G. A., Kockeritz, L. K., and 
Woodgett, J. R. Functional redundancy of GSK-3alpha and 
GSK-3beta in Wnt/beta-catenin signaling shown by using 
an allelic series of embryonic stem cell lines. Dev Cell. 
2007; 12: 957-971.
21. Kleppe, M., and Levine, R. L. Targeting beta-catenin in 
CML: leukemia stem cells beware! Cell Stem Cell. 2012; 
10: 351-353.
22. Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., 
Cook, J. M., Lagoo, A., and Reya, T. Loss of beta-catenin 
impairs the renewal of normal and CML stem cells in vivo. 
Cancer Cell. 2007; 12: 528-541.
23. MacDonald, B. T., Tamai, K., and He, X. Wnt/beta-catenin 
signaling: components, mechanisms, and diseases. Dev 
Cell. 2009; 17: 9-26.
24. Wassermann, S., Scheel, S. K., Hiendlmeyer, E., Palmqvist, 
R., Horst, D., Hlubek, F., Haynl, A., Kriegl, L., Reu, S., 
Merkel, S., Brabletz, T., Kirchner, T., and Jung, A. 
p16INK4a is a beta-catenin target gene and indicates low 
survival in human colorectal tumors. Gastroenterology. 
2009; 136: 196-205 e192.
25. Kolligs, F. T., Hu, G., Dang, C. V., and Fearon, E. R. 
Neoplastic transformation of RK3E by mutant beta-catenin 
requires deregulation of Tcf/Lef transcription but not 
activation of c-myc expression. Mol Cell Biol. 1999; 19: 
5696-5706.
26. Kuhl, S. J., and Kuhl, M. On the role of Wnt/beta-catenin 
signaling in stem cells. Biochim Biophys Acta. 2013; 1830: 
2297-2306.
27. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., 
Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, 
K., Wang, C. Y., He, X., MacDougald, O. A., You, M., 
Williams, B. O., and Guan, K. L. TSC2 integrates Wnt and 
energy signals via a coordinated phosphorylation by AMPK 
and GSK3 to regulate cell growth. Cell. 2006; 126: 955-968.
28. Ballou, L. M., and Lin, R. Z. Rapamycin and mTOR kinase 
inhibitors. J Chem Biol. 2008; 1: 27-36.
29. Laplante, M., and Sabatini, D. M. mTOR signaling in 
growth control and disease. Cell. 2012; 149: 274-293.
30. Choo, A. Y., Roux, P. P., and Blenis, J. Mind the GAP: Wnt 
steps onto the mTORC1 train. Cell. 2006; 126: 834-836.
31. Gormand, A., Henriksson, E., Strom, K., Jensen, T. E., 
Sakamoto, K., and Goransson, O. Regulation of AMP-
activated protein kinase by LKB1 and CaMKK in 
adipocytes. J Cell Biochem. 2011; 112: 1364-1375.
32. Inoki, K., Zhu, T., and Guan, K. L. TSC2 mediates cellular 
energy response to control cell growth and survival. Cell. 
2003; 115: 577-590.
33. Study of AR-12 in adult patients with advanced or recurrent 
solid tumors or lymphoma, 2013.
34. Johnson, A. J., Smith, L. L., Zhu, J., Heerema, N. A., 
Jefferson, S., Mone, A., Grever, M., Chen, C. S., and Byrd, 
J. C. A novel celecoxib derivative, OSU03012, induces 
cytotoxicity in primary CLL cells and transformed B-cell 
lymphoma cell line via a caspase- and Bcl-2-independent 
mechanism. Blood. 2005; 105: 2504-2509.
35. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-
Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, 
N., Hirshman, M.F., Goodyear, L.J., Moller, D.E. Role of 
AMP-activated protein kinase in mechanism of metformin 
action. J Clin Invest. 2001; 108: 1167-1174.
Oncotarget81570www.impactjournals.com/oncotarget
36. Loewe, S. The problem of synergism and antagonism of 
combined drugs. Arzneimittelforschung. 1953; 3: 285-290.
37. Perrotti, D., Jamieson, C., Goldman, J., Skorski, T. Chronic 
myeloid leukemia: mechanisms of blastic transformation. J 
Clin Invest. 2010; 120, 2254-2264.
38. Subhashini, J., Mahipal, S. V., and Reddanna, P. Anti-
proliferative and apoptotic effects of celecoxib on human 
chronic myeloid leukemia in vitro. Cancer Lett. 2005; 224: 
31-43.
39. Williams, C. S., Watson, A. J., Sheng, H., Helou, R., Shao, 
J., and DuBois, R. N. Celecoxib prevents tumor growth 
in vivo without toxicity to normal gut: lack of correlation 
between in vitro and in vivo models. Cancer Res. 2000; 60: 
6045-6051.
40. Zhang, G. S., Liu, D. S., Dai, C. W., and Li, R. J. Antitumor 
effects of celecoxib on K562 leukemia cells are mediated by 
cell-cycle arrest, caspase-3 activation, and downregulation 
of COX2 expression and are synergistic with hydroxyurea 
or imatinib. Am J Hematol. 2006; 81: 242-255.
41. Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., 
Xu, Y., Birnbaum, M. J., and Thompson, C. B. AMP-
activated protein kinase induces a p53-dependent metabolic 
checkpoint. Mol Cell. 2005; 18: 283-293.
42. Sharpless, N. E., and Sherr, C. J. Forging a signature of in 
vivo senescence. Nat Rev Cancer. 2015; 15: 397-408.
43. Kim, J., Kundu, M., Viollet, B., and Guan, K. L. AMPK and 
mTOR regulate autophagy through direct phosphorylation 
of Ulk1. Nat Cell Biol. 2011; 13: 132-141.
44. Reddiconto, G., Toto, C., Palama, I., De Leo, S., de Luca, 
E., De Matteis, S., Dini, L., Passerini, C. G., Di Renzo, N., 
Maffia, M., and Coluccia, A. M. Targeting of GSK3beta 
promotes imatinib-mediated apoptosis in quiescent CD34+ 
chronic myeloid leukemia progenitors, preserving normal 
stem cells. Blood. 2012; 119: 2335-2345.
45. Maier, T. J., Janssen, A., Schmidt, R., Geisslinger, G., and 
Grosch, S. Targeting the beta-catenin/APC pathway: a novel 
mechanism to explain the cyclooxygenase-2-independent 
anticarcinogenic effects of celecoxib in human colon 
carcinoma cells. FASEB J. 2005; 19: 1353-1355.
46. Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. 
V., Soliera, A. R., Ronchetti, M., Galavotti, S., Young, K. 
W., Selmi, T., Yacobi, R., Van Etten, R. A., Donato, N., 
Hunter, A., Dinsdale, D., Tirro, E., Vigneri, P., Nicotera, P., 
Dyer, M. J., Holyoake, T., Salomoni, P., and Calabretta, B. 
Targeting autophagy potentiates tyrosine kinase inhibitor-
induced cell death in Philadelphia chromosome-positive 
cells, including primary CML stem cells. J Clin Invest. 
2009; 119: 1109-1123.
47. Mathew, R., Karantza-Wadsworth, V., and White, E. Role 
of autophagy in cancer. Nat Rev Cancer. 2007; 7: 961-967.
48. Carayol, N., Vakana, E., Sassano, A., Kaur, S., Goussetis, 
D. J., Glaser, H., Druker, B. J., Donato, N. J., Altman, J. K., 
Barr, S., and Platanias, L. C. Critical roles for mTORC2- 
and rapamycin-insensitive mTORC1-complexes in growth 
and survival of BCR-ABL-expressing leukemic cells. Proc 
Natl Acad Sci U S A. 2010; 107: 12469-12474.
49. Paulson, S. K., Zhang, J. Y., Breau, A. P., Hribar, J. D., 
Liu, N. W., Jessen, S. M., Lawal, Y. M., Cogburn, J. N., 
Gresk, C. J., Markos, C. S., Maziasz, T. J., Schoenhard, G. 
L., and Burton, E. G. Pharmacokinetics, tissue distribution, 
metabolism, and excretion of celecoxib in rats. Drug Metab 
Dispos. 2000; 28: 514-521.
50. Bartholomeusz, G. A., Talpaz, M., Kapuria, V., Kong, 
L. Y., Wang, S., Estrov, Z., Priebe, W., Wu, J., Donato, 
N. J. Activation of a novel Bcr/Abl destruction pathway 
by WP1130 induces apoptosis of chronic myelogenous 
leukemia cells. Blood. 2007; 109: 3470–3478.
51. Mahon, F. X., Deininger, M. W., Schultheis, B., Chabrol, 
J., Reiffers, J., Goldman, J. M., Melo J. V. Selection and 
characterization of BCR-ABL positive cell lines with 
differential sensitivity to the tyrosine kinase inhibitor 
STI571: diverse mechanisms of resistance. Blood. 2000; 
96: 1070-9.
52. Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., 
Arlinghaus, R., Talpaz, M. BCR-ABL independence 
and Lyn kinase overexpression in chronic myelogenous 
leukemia cells selected for resistance to STI571. Blood. 
2003; 101: 690–698.
53. Reddy, A. R., Sampath, A., Goverdhan, G., Yakambaram, 
B., Mukkanti, K., and Reddy, P. P.. An improved and 
scalable process for celecoxib: a selective cyclooxygenase-2 
inhibitor. Org Process Res Dev. 2009; 13: 98-101.
54. Condorelli, F., Gnemmi, I., Vallario, A., Genazzani, A. 
A., and Canonico, P. L. Inhibitors of histone deacetylase 
(HDAC) restore the p53 pathway in neuroblastoma cells. 
Br J Pharmacol. 2008; 153: 657-668.
